Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Science. Author manuscript; available in PMC Oct 9, 2010.
Published in final edited form as:
PMCID: PMC2882032
NIHMSID: NIHMS203374

KLF Family Members Regulate Intrinsic Axon Regeneration Ability

Abstract

Neurons in the central nervous system (CNS) lose their ability to regenerate early in development, but the underlying mechanisms are unknown. By screening genes developmentally regulated in retinal ganglion cells (RGCs), we identified Krüppel-like factor–4 (KLF4) as a transcriptional repressor of axon growth in RGCs and other CNS neurons. RGCs lacking KLF4 showed increased axon growth both in vitro and after optic nerve injury in vivo. Related KLF family members suppressed or enhanced axon growth to differing extents, and several growth-suppressive KLFs were up-regulated postnatally, whereas growth-enhancing KLFs were down-regulated. Thus, coordinated activities of different KLFs regulate the regenerative capacity of CNS neurons.

Adult mammalian central nervous system (CNS) axons are unable to regenerate after injury, but immature CNS neurons regenerate axons robustly (13). In addition to the development of an inhibitory CNS environment (4, 5), a developmental loss in neurons’ intrinsic capacity for axon growth is thought to contribute to regeneration failure. For example, after birth, axonal outgrowth from rat retinal ganglion cells (RGCs, a type of CNS neuron) slows substantially (6). Similar developmental declines in axon growth ability have been observed in mammalian tissue explants of brainstem (7), cerebellum (8, 9), entorhinal cortex (10), and retina (2). Various cell-autonomous factors such as cAMP (cyclic adenosine 3′,5′-monophosphate) and CREB (cAMP response element–binding protein) (11, 12), Bcl-2 (B cell lymphoma/leukemia 2) (13, 14), Rho/ROCK (Rho-associated kinase) (15), Cdh1-APC (anaphase-promoting complex) (16, 17), and PTEN (phosphatase and tensin homolog) (18) have been suggested to play roles in this process. However, manipulating these regulators of axon growth, even when simultaneously overcoming environmental inhibition, only partially restores regeneration, suggesting that additional intrinsic axon growth regulators remain to be identified.

To investigate the molecular basis for the developmental loss of axon growth ability in RGCs, we took advantage of the fact that coculture with amacrine cell membranes is sufficient to signal embryonic RGCs to decrease their rapid axon growth (6). Addition of the transcriptional inhibitor actinomycin D blocked this effect of amacrine membranes, and embryonic RGCs retained their capacity for axon growth (Fig. 1A). These data suggest that gene transcription is required for the developmental loss of intrinsic axon growth ability in RGCs.

Fig. 1
A screen of developmentally regulated genes identifies KLF4 as an inhibitor of neurite growth. (A) Purified embryonic RGCs were cultured in the presence (white bars) or absence (black bars) of amacrine cell membranes for 3 days, and replated away from ...

To identify candidate genes, we profiled gene expression from embryonic day 17 (E17) through postnatal day 21 (P21) RGCs (19), spanning the period when axon growth ability declines in vivo (6, 13). We screened 111 candidates whose expression changed more than threefold by over-expression in embryonic hippocampal neurons, and used automated image acquisition and neurite tracing (KSR instrument, Cellomics) for rapid, unbiased quantification of neurite length (20); the investigator (D.L.M.) was blinded to gene identity until the screen was complete. The zinc-finger transcription factor, Krüppel-like factor–4 (KLF4), was the most effective suppressor of neurite outgrowth, decreasing average length by 50% (Fig. 1B). In a separate, blinded screen examining growth cone morphologies, KLF4 again emerged as the most interesting candidate gene as growth cones in KLF4-overexpressing hippocampal neurons were consistently enlarged (e.g., Fig. 1C).

Although KLF4 regulates cell survival in other systems (2123), we detected no differences in survival between KLF4- and control-transfected hippocampal neurons (fig. S1A). To determine if the growth-suppressive effect was specific either to axons or dendrites, we manually traced Tau+ and MAP2+ neurites (fig. S1B). Overexpression of KLF4 in embryonic hippocampal neurons significantly decreased the lengths of both axons (Tau+/MAP2−) and dendrites (Tau+/MAP2+) (figs. S1 and S2). We also observed a reduction in branching (fig. S3) and in the percentage of neurons that extended neurites (fig. S1C). Taken together, these findings suggest that KLF4 acts independently of cell survival to suppress axon and dendrite initiation and elongation by hippocampal neurons in vitro.

We next asked whether KLF4 regulates axon growth of RGCs. KLF4 expression increased postnatally, both by microarray analysis (19) (Fig. 2A) and by quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR; Fig. 2B) of acutely purified RGCs. We purified RGCs from E20 rats and transfected them with FLAG-tagged KLF4 (24) or a FLAG-only control. Overexpression of KLF4 in embryonic RGCs reduced the percentage of neurons extending neurites (Fig. 2E), reduced neurite branching (fig. S4), and reduced axon and, less so, dendrite lengths (Fig. 2, C and D). The average axon length of KLF4-transfected RGCs continued to increase over 3 days, but at a slower rate than control-transfected neurons (fig. S5), suggesting that KLF4 overexpression decreases elongation rate. Furthermore, truncated KLF4 that lacked a C-terminal DNA binding domain (fig. S2A) (24) had no effect on axon growth (Fig. 2, C and D). Thus, KLF4 suppresses axon growth in embryonic RGCs, and KLF4’s DNA binding domain is required for its growth-suppressive activity.

Fig. 2
KLF4 is developmentally regulated in RGCs, and its overexpression decreases axon growth in a zinc-finger–dependent manner. (A and B) KLF4 expression in RGCs increases at birth, as measured in acutely purified rat RGCs by microarray [three probe ...

We next tested whether knocking out KLF4 in developing RGCs enhances axon growth ability. Because KLF4-null mice die perinatally (25), we used a Cre/lox strategy to target KLF4 knockout to RGCs. Floxed-KLF4 mice (26) were crossed to ROSA-EYFP (enhanced yellow fluorescent protein) reporter mice and Thy-1–promoter Cre recombinase mice. About 50% of RGCs purified from Thy-1-cre/ROSA-EYFP mice were EYFP+ (fig. S6). There was no effect of transgenic Cre expression on RGC neurite growth, neurite initiation, or survival in vitro (figs. S7 and S8). To examine axon growth from KLF4-deficient RGCs in vitro, we purified RGCs from P12 Thy1-cre+/−/KLF4fl/fl/ROSA-EYFP+ (“KO”) or Thy1-cre−/ −/KLF4fl/fl/ROSA-EYFP+ (“WT”) littermate mice and cultured them for 3 days (Fig. 3A). No effect of KLF4-KO was seen on survival (fig. S8). P12 KLF4-KO RGCs showed a statistically significant increase in neurite initiation compared to controls (Fig. 3B), mirroring our previous finding that overexpression of KLF4 decreases neurite initiation (Fig. 2E). We also observed a significant increase in neurite lengths in KLF4-KO RGCs (Fig. 3C). These data demonstrate that knocking out KLF4 enhances axon growth ability in P12 RGCs in vitro.

Fig. 3
KLF4 knockout increases RGC neurite growth in vitro and regeneration of adult RGCs in vivo. (A to C) Purified P12 RGCs were cultured from Thy1-cre−/ −/KLF4fl/fl/Rosa+ (Cre− WT) and Thy1-cre+/−/KLF4fl/fl/Rosa+ (Cre+ KO) ...

We next asked if knocking out KLF4 during development enhances regeneration from adult RGCs in vivo. Thy1-cre+/KLF4fl/fl (KO), Thy1-cre+/KLF4fl/+ (Het), or Thy1-cre+/KLF4+/+ (WT) littermate mice were subjected to optic nerve crush, and after 2 weeks we assessed regeneration of RGC axons in the optic nerve. By adulthood, there were no differences in RGC number between KO, Het, and WT animals (fig. S9A). Compared to controls, however, KLF4 KO mice showed an increased number of regenerating axons at multiple distances from the injury site (Fig. 3, D and E). KLF4 KO did not affect RGC survival after injury (fig. S9B), showing that this increase in regenerating axons was not secondary to an increased RGC number. Thus, knocking out KLF4 expression during development increases the regenerative potential of adult RGCs.

Although knocking out KLF4 enhanced axon growth and regeneration, the size of the effect led us to speculate that other KLF family members might compensate for the loss of KLF4. The KLF family comprises 17 related transcription factors with homologous DNA binding domains and divergent activation and repression domains (27). KLFs often regulate gene expression interactively, with both cooperative and competitive relationships among family members (2830). Our microarray data suggested that many KLFs are expressed by RGCs (19) and that some are developmentally regulated (fig. S10). We reprofiled the expression of all 17 KLF family members in developing RGCs by RT-PCR and detected transcripts for 15 (Fig. 4E). Furthermore, qRT-PCR revealed that KLF6 and KLF7 transcripts decrease more than 10-fold, whereas KLF9 increases more than 250-fold (Fig. 4, A to C). Thus, expression of multiple KLFs is regulated in developing RGCs.

Fig. 4
Multiple KLF family members are developmentally regulated in RGCs and differentially affect CNS neurite growth. (A to C) RGCs from multiple ages were purified by immunopanning and analyzed by qRT-PCR. Transcript abundance is normalized to E19. KLF6 (A) ...

Do other KLF family members also regulate neurite growth? Other KLFs can affect neurite branching in response to thyroid hormone (KLF9) (31) or neurite outgrowth in zebrafish retinal explants (KLF6 and -7) (32). In RGCs, overexpression of KLF9 significantly decreased growth, similar to KLF4, and KLF6 and -7 increased neurite growth 13 and 23%, respectively (Fig. 4D). We comprehensively surveyed all 17 KLF family members’ on neurite growth in cortical neurons in vitro, and found that although no KLFs affected cell survival (fig. S11), eight KLFs, including KLF4 and -9, suppressed neurite growth, and KLF6 and -7 again significantly increased neurite growth, 35 and 60%, respectively (Fig. 4E). As with KLF4, effects on neurite growth depended on the DNA binding domain (figs. S12 and S13). Clustering KLFs by sequence similarity revealed an association between functional domains (27) and effects on neurite outgrowth (Fig. 4E). For instance, overexpression of the BTEB cluster and the cluster containing KLF4 (orange and pink bars, respectively, Fig. 4E) decreased neurite growth. The TIEG and PVALS/T (33)–containing clusters (blue and green bars, Fig. 4E) had no effect on neurite length. KLF6 and KLF7, with 85% homologous activation domains, both increased neurite length (yellow bars, Fig. 4E). To explore coordinate regulation of neurite growth by KLFs, we coexpressed all two-way combinations of KLFs -4, -6, -7, and -9 in cortical neurons. The negative effects of KLF4 on neurite growth were dominant over the otherwise positive effects of KLF6 or -7; the negative effects of KLF9 summed with those of KLF6 or -7 to no net effect (Fig. 4F), suggesting a complexity to KLF-KLF interactions in regulating neurite growth. Thus, during development, RGCs down-regulate at least two growth-enhancing KLFs (KLF6 and -7), and up-regulate at least two growth-suppressive KLFs (KLF4 and -9), which may be dominant in their effect over KLF6 and -7.

These findings that the KLF family of transcription factors regulates axon growth in a number of CNS neurons have important implications. First, although KLF4 has been implicated in a wide variety of cellular events including differentiation (34, 35), cancer progression (3638), and stem cell reprogramming (39), this function for KLF4 in postmitotic neurons advances our knowledge of the transcriptional regulation of axon regeneration. KLF4 targets relevant for regeneration may include genes selectively expressed in neurons or important in growth cone function. Second, the clustering of KLF gene function according to domain homology may provide a key for understanding how KLFs cooperate and compete to determine cellular phenotype, whether for axon regeneration or for other systems (27). Third, the decrease in RGCs’ intrinsic axon growth ability (6) parallels changes in expression within the KLF family: Postnatal RGCs express higher levels of axon growth-suppressing KLFs and lower levels of axon growth-enhancing KLFs; similar changes can be found in published corticospinal motor neuron data (40). Thus, manipulating multiple KLF genes may be a useful strategy to add to existing approaches to increase the intrinsic regenerative capacity of mature CNS neurons damaged by injury or disease.

Supplementary Material

Acknowledgments

This work was funded by a National Eye Institute (NEI) R03 grant (EY016790, J.L.G.) and subsequently by a National Institute of Neurological Disorders and Stroke (NINDS) R01 grant (NS061348, J.L.G.) and critical funding from The Glaucoma Foundation and the Seigal Foundation (J.L.G.), the C. H. Neilsen Foundation (V.P.L. and J.L.G.), the Ralph Wilson Medical Research Foundation and the W.G. Ross Foundation (V.P.L.), The Buoniconti Fund to Cure Paralysis (V.P.L. and J.L.B.), an NEI P30 grant (EY014801), and an unrestricted grant from Research to Prevent Blindness to the University of Miami. D.L.M. is a Lois Pope LIFE Fellow, with support from NINDS training grants T32 NS07492 and T32 NS007459. We are indebted for generous gifts of FLAG-tagged KLF4 (C. Liu, University of Texas), mCherry (R. Tsien, University of California, San Diego), and KLF2 constructs (J. Lingrel, University of Cincinnati). We are grateful to W. Feuer (University of Miami) for statistical contributions and to R. Corredor (University of Miami) for optimizing RGC electroporation. We thank the following lab members and collaborators for their meaningful contributions: Ne. Patel, Ni. Patel, J. Gallardo, N. Sharifai, E. Walford, M. Velarde, A. Sloan, M. Benny, A. Oliva, Y. Shi, E. Hernandez, G. Lambert, and G. Gaidosh. The authors declare they have no conflicts of interest.

References and Notes

1. Nicholls J, Saunders N. Trends Neurosci. 1996;19:229. [PubMed]
2. Chen DF, Jhaveri S, Schneider GE. Proc Natl Acad Sci USA. 1995;92:7287. [PMC free article] [PubMed]
3. Bregman BS, Kunkel-Bagden E, McAtee M, O’Neill A. J Comp Neurol. 1989;282:355. [PubMed]
4. Yiu G, He Z. Nat Rev Neurosci. 2006;7:617. [PMC free article] [PubMed]
5. Case LC, Tessier-Lavigne M. Curr Biol. 2005;15:R749. [PubMed]
6. Goldberg JL, Klassen MP, Hua Y, Barres BA. Science. 2002;296:1860. [PubMed]
7. Blackmore M, Letourneau PC. J Neurobiol. 2006;66:348. [PubMed]
8. Dusart I, Airaksinen MS, Sotelo C. J Neurosci. 1997;17:3710. [PubMed]
9. Bouslama-Oueghlani L, Wehrle R, Sotelo C, Dusart I. J Neurosci. 2003;23:8318. [PubMed]
10. Li D, Field PM, Raisman G. Eur J Neurosci. 1995;7:1164. [PubMed]
11. Cai D, et al. J Neurosci. 2001;21:4731. [PubMed]
12. Gao Y, et al. Neuron. 2004;44:609. [PubMed]
13. Chen DF, Schneider GE, Martinou JC, Tonegawa S. Nature. 1997;385:434. [PubMed]
14. Cho KS, et al. J Cell Sci. 2005;118:863. [PMC free article] [PubMed]
15. Lehmann M, et al. J Neurosci. 1999;19:7537. [PubMed]
16. Konishi Y, Stegmuller J, Matsuda T, Bonni S, Bonni A. Science. 2004;303:1026. [PubMed]
17. Lasorella A, et al. Nature. 2006;442:471. [PubMed]
18. Park KK, et al. Science. 2008;322:963. [PMC free article] [PubMed]
19. Wang JT, et al. J Neurosci. 2007;27:8593. [PMC free article] [PubMed]
20. Buchser WJ, Pardinas JR, Shi Y, Bixby JL, Lemmon VP. Biotechniques. 2006;41:619. [PMC free article] [PubMed]
21. Zhu S, Tai C, MacVicar BA, Jia W, Cynader MS. Brain Res. 2009;1250:49. [PubMed]
22. Ghaleb AM, Katz JP, Kaestner KH, Du JX, Yang VW. Oncogene. 2007;26:2365. [PMC free article] [PubMed]
23. Hagos EG, Ghaleb AM, Dalton WB, Bialkowska AB, Yang VW. Oncogene. 2009;28:1197. [PMC free article] [PubMed]
24. Zhang W, et al. Mol Cell Biol. 2006;26:2055. [PMC free article] [PubMed]
25. Segre JA, Bauer C, Fuchs E. Nat Genet. 1999;22:356. [PubMed]
26. Katz JP, et al. Development. 2002;129:2619. [PMC free article] [PubMed]
27. Kaczynski J, Cook T, Urrutia R. Genome Biol. 2003;4:206. [PMC free article] [PubMed]
28. Jiang J, et al. Nat Cell Biol. 2008;10:353. [PubMed]
29. Eaton SA, et al. J Biol Chem. 2008;283:26937. [PMC free article] [PubMed]
30. Dang DT, Zhao W, Mahatan CS, Geiman DE, Yang VW. Nucleic Acids Res. 2002;30:2736. [PMC free article] [PubMed]
31. Cayrou C, Denver RJ, Puymirat J. Endocrinology. 2002;143:2242. [PubMed]
32. Veldman MB, Bemben MA, Thompson RC, Goldman D. Dev Biol. 2007;312:596. [PubMed]
33. Abbreviations for the amino acid residues are as follows: A, Ala; E, Glu; G, Gly; I, Ile; L, Leu; P, Pro; S, Ser; T, Thr; and V, Val.
34. Ghaleb AM, et al. Cell Res. 2005;15:92. [PMC free article] [PubMed]
35. Dai X, Segre JA. Curr Opin Genet Dev. 2004;14:485. [PMC free article] [PubMed]
36. Rowland BD, Peeper DS. Nat Rev Cancer. 2006;6:11. [PubMed]
37. Safe S, Abdelrahim M. Eur J Cancer. 2005;41:2438. [PubMed]
38. Black AR, Black JD, Azizkhan-Clifford J. J Cell Physiol. 2001;188:143. [PubMed]
39. Zhao R, Daley GQ. J Cell Biochem. 2008;105:949. [PubMed]
40. Arlotta P, et al. Neuron. 2005;45:207. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...